The diagnosis of Cushing's syndrome: an Endocrine Society Clinical Practice Guideline.
Open accessThe DOI matches its Crossref record; 119 of the 140 references it cites were found in a registry or an index; 9 of the 77 sources its claims cite were checked for support.
Abstract
OBJECTIVE: The objective of the study was to develop clinical practice guidelines for the diagnosis of Cushing's syndrome. PARTICIPANTS: The Task Force included a chair, selected by the Clinical Guidelines Subcommittee (CGS) of The Endocrine Society, five additional experts, a methodologist, and a medical writer. The Task Force received no corporate funding or remuneration. CONSENSUS PROCESS: Consensus was guided by systematic reviews of evidence and discussions. The guidelines were reviewed and approved sequentially by The Endocrine Society's CGS and Clinical Affairs Core Committee, members responding to a web posting, and The Endocrine Society Council. At each stage the Task Force incorporated needed changes in response to written comments. CONCLUSIONS: After excluding exogenous glucocorticoid use, we recommend testing for Cushing's syndrome in patients with multiple and progressive features compatible with the syndrome, particularly those with a high discriminatory value, and patients with adrenal incidentaloma. We recommend initial use of one test with high diagnostic accuracy (urine cortisol, late night salivary cortisol, 1 mg overnight or 2 mg 48-h dexamethasone suppression test). We recommend that patients with an abnormal result see an endocrinologist and undergo a second test, either one of the above or, in some cases, a serum midnight cortisol or dexamethasone-CRH test. Patients with concordant abnormal results should undergo testing for the cause of Cushing's syndrome. Patients with concordant normal results should not undergo further evaluation. We recommend additional testing in patients with discordant results, normal responses suspected of cyclic hypercortisolism, or initially normal responses who accumulate additional features over time.
Overview
CoChat Summary
TL;DR
This Endocrine Society guideline recommends case detection for Cushing's syndrome only in selected high-risk groups, initial testing with one of four high-accuracy tests, and confirmatory second testing before cause-directed evaluation. It emphasizes excluding exogenous glucocorticoids first and notes that most recommendations rest on very low- to low-quality evidence.
Key findings
- Exclude exogenous glucocorticoid exposure before biochemical testing (1QQQQ); test patients with multiple and progressive features, unusual features for age, children with decreasing height percentile and increasing weight, or adrenal incidentaloma compatible with adenoma, and recommend against widespread testing in other groups.
- Initial testing should use one of: urine free cortisol (at least two measurements), late-night salivary cortisol (two measurements), 1-mg overnight dexamethasone suppression test, or 48-h 2 mg/d dexamethasone suppression test; recommend against random serum cortisol/plasma ACTH, urinary 17-ketosteroids, insulin tolerance test, loperamide test, and cause-directed tests for initial diagnosis.
- Reported test performance includes late-night salivary cortisol sensitivity 92–100% and specificity 93–100%; pediatric UFC sensitivity about 89%; 1-mg DST at a 1.8 µg/dL cutoff sensitivity >95% with specificity 80%, rising to >95% specificity at a 5 µg/dL threshold; LDDST sensitivity 96% and specificity 70%; dexamethasone-CRH sensitivity 98% and specificity 60%.
- Special-population recommendations: use UFC and avoid dexamethasone testing in pregnancy; avoid dexamethasone testing with enzyme-inducing antiepileptics; suggest 1-mg overnight DST rather than UFC in severe renal failure; suggest UFC or midnight salivary cortisol rather than DSTs in suspected cyclic Cushing's; suggest 1-mg DST or late-night cortisol rather than UFC in adrenal incidentaloma.
Methods
- A six-member Task Force appointed by The Endocrine Society's Clinical Guidelines Subcommittee, including a chair, five additional experts, a methodologist, and a medical writer, received no corporate funding or remuneration; consensus was guided by systematic reviews and discussions and approved sequentially by Society bodies and members.
- Recommendations used the GRADE approach: strong recommendations phrased “we recommend” with number 1, weak recommendations “we suggest” with number 2; evidence quality ranged from QEEE (very low) to QQQQ (high), informed by best available research evidence and systematic reviews/meta-analyses of test accuracy.
- The guideline presents evidence, values, and remarks linked to each recommendation; technical remarks often reflect the panel's unsystematic observations applied to a typical patient.
Limitations
- Stated: the majority of recommendations are based on very low- to low-quality evidence, with limited data linking diagnostic strategies to patient-important outcomes and no higher-quality direct evidence available.
- Stated: published data often come from larger tertiary referral centers and may be biased toward more diagnostically challenging cases, higher pretest probability, and greater disease severity, potentially giving an overly sanguine view of test performance in unselected populations.
- Evident from the text: this is a consensus guideline rather than a primary study, and some technical recommendations rest on unsystematic panel observations; data on treating mild/subclinical Cushing's syndrome and adrenal incidentaloma are described as limited and conflicting.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
8 Valid · 4 Not valid · 37 Not checked · 33 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Another study of 86 consecutive obese subjects referred to an endocrine clinic with diabetes mellitus, hypertension, and/or the polycystic ovary syndrome found a 5.8% incidence of Cushing's syndrome (35).”
§ The Diagnosis of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline > 3.3 Evidence
What the sources say
- Partly supportedcites [35] 35. Ness-Abramof R, Nabriski D, Apovian CM, Niven M, Weiss E, Shapiro MS, Shenkman L 2002 Overnight dexamethasone suppression test: a reliable screen for Cushing's syndrome in the obese. Obes Res 10:1217-1221 sourceExperimental — accuracy not yet measured
The Patients section describes 86 obese patients referred to an endocrine clinic, and the Results report five Cushing’s syndrome diagnoses—5/86, or approximately 5.8%, though the paper prints 5.7%. The copy does not say the patients were consecutive. It also reports that 51 had obesity alone, so diabetes, hypertension, and polycystic ovary disease do not describe the whole group. (LLM, conf=0.87)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“The salivary glands express 11-hydroxysteroid dehydrogenase type 2 (11-HSD2), which converts the biologically active cortisol to inactive cortisone (75).”
§ The Diagnosis of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline > 3.4.2 Remarks for late-night salivary cortisol
What the sources say
- Supportedcites [75] 75. Smith RE, Maguire JA, Stein-Oakley AN, Sasano H, Takahashi K, Fuku- shima K, Krozowski ZS 1996 Localization of 11-hydroxysteroid dehydro- genase type II in human epithelial tissues. J Clin Endocrinol Metab 81:3244 - 3248 source
The paper reports 11β-HSD2 in the ducts of human parotid and submandibular salivary glands (Abstract; Discussion, p. 3247). It describes the enzyme as inactivating glucocorticoids and discusses salivary cortisol-to-cortisone ratios (Introduction; Discussion, p. 3247), supporting the stated function. (LLM, conf=0.87)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Overall, the evidence in adults suggests that the accuracy of this test is similar to that of UFC (2).”
§ The Diagnosis of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline > 3.4.2 Evidence for late-night salivary cortisol
What the sources say
- Supportedcites [2] 2. Elamin MB, Murad MH, Mullan R, Erickson D, Harris K, Nadeem S, Ennis R, Erwin PJ, Montori VM 2008 Accuracy of diagnostic tests for Cushing syndrome: a systematic review and meta-analyses. J Clin Endocrinol Metab 93:1553-1562 source
Table 3 (Conclusions; page unavailable) reports broadly similar pooled diagnostic likelihood ratios for midnight salivary cortisol and UFC. The Summary of findings notes that evidence for salivary cortisol is more limited, consistent with the citing sentence’s cautious wording. (LLM, conf=0.88)
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“When the assay upper limit of normal is used as a criterion, the overall evidence supports the diagnostic accuracy of UFC in adults suspected of having Cushing's syndrome (2,51).”
§ The Diagnosis of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline > 3.4.1 Evidence for use of UFC
What the sources say
- Partly supportedcites [2] 2. Elamin MB, Murad MH, Mullan R, Erickson D, Harris K, Nadeem S, Ennis R, Erwin PJ, Montori VM 2008 Accuracy of diagnostic tests for Cushing syndrome: a systematic review and meta-analyses. J Clin Endocrinol Metab 93:1553-1562 sourceExperimental — accuracy not yet measured
The Summary of findings says UFC has substantial evidence supporting its use to detect Cushing’s syndrome, and the pooled results table reports diagnostic accuracy across 14 UFC studies. The Subgroup analyses section identifies an assay-upper-limit cutoff, but the reported UFC estimate is pooled across studies rather than shown specifically for that cutoff. The Conclusions also limit the apparent accuracy to referral practices enriched with patients with Cushing’s syndrome; performance in usual clinical practice remains unclear. Page numbers were not available in our copy. (LLM, conf=0.83)
- Supportedcites [51] 51. Pecori Giraldi F, Ambrogio AG, De Martin M, Fatti LM, Scacchi M, Cav- agnini F 2007 Specificity of first-line tests for the diagnosis of Cushing's syndrome: assessment in a large series. J Clin Endocrinol Metab 92:4123- 4129 source
The UFC results (p. 2) report 91.2% specificity in Cushing’s syndrome suspects when values above the assay’s reference range were considered abnormal. The Discussion (p. 5) identifies that threshold as the assay’s upper limit of normal and describes UFC as having superior diagnostic performance. The study assessed specificity, rather than diagnostic accuracy across all measures. (LLM, conf=0.88)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The four recommended tests have acceptable diagnostic accuracy when the suggested cutoff points are used (2,30).”
§ The Diagnosis of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline > 3.4 Evidence
What the sources say
- Partly supportedcites [2] 2. Elamin MB, Murad MH, Mullan R, Erickson D, Harris K, Nadeem S, Ennis R, Erwin PJ, Montori VM 2008 Accuracy of diagnostic tests for Cushing syndrome: a systematic review and meta-analyses. J Clin Endocrinol Metab 93:1553-1562 sourceExperimental — accuracy not yet measured
The Conclusions state that commonly used tests appear highly accurate in referral practices with samples enriched for Cushing’s syndrome, but that their performance in usual clinical practice is unclear. The Data extraction section says the review used cutoffs chosen by the primary studies, selecting those with the best performance when several were available; it does not establish accuracy specifically at the suggested cutoff points. (LLM, conf=0.85)
- Not checked — no full text of the sourcecites [30] 30. Batista DL, Riar J, Keil M, Stratakis CA 2007 Diagnostic tests for children who are referred for the investigation of Cushing syndrome. Pediatrics 120: e575-e586 source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
48 more claims · 3 with their cited sources checked
Create a free account to see all 82 claims and to verify the 1 reference still open.
- Probably not a substantial claim. 12
- It may state two separate claims as one. 20
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Early diagnosis of secondary hypertension and the institution of appropriate targeted treatment have the potential to cure hypertension in some patients or improve BP control/reduce the number of prescribed antihypertensive medications in others.”
From 2020 International Society of Hypertension Global Hypertension Practice Guidelines (2020) · cites this paper as [118]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Therefore, accurate serum cortisol measurement is essential for the correct diagnosis and management of adrenal pathologies.”
From Serum cortisol: an up-to-date assessment of routine assay performance (2016) · cites this paper as [2]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“the reliability of almost all markers of HPA axis activity, particularly ACTH and 24-h urinary free cortisol (UFC), is low (3,14,23)”
From Diagnosis and Treatment of Subclinical Hypercortisolism (2011) · cites this paper as [14]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Therefore, UFC should not be considered an adequate screening test for SH and should be used in combination with other tests or in specific populations (1,14).”
From Diagnosis and Treatment of Subclinical Hypercortisolism (2011) · cites this paper as [14]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“some authors have proposed higher (3 or 8 mg) dexamethasone doses (40,46,54,56), which however did not show a better performance (14,23,66).”
From Diagnosis and Treatment of Subclinical Hypercortisolism (2011) · cites this paper as [14]
Experimental — accuracy not yet measured
27 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ The Diagnosis of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline > 3.2 Evidence
“biochemical hypercortisolism is present in a large fraction (up to 10%).”
§ The Diagnosis of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline > 3.2 Evidence
“Libe et al. (32) reported 18%; Terzolo et al. (21) quoted 5-20%, depending on referral bias and diagnostic tests and criteria.”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ The Diagnosis of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline > Subsequent evaluation
“3.9.1 We suggest the additional use of the dexamethasone-CRH test or the midnight serum cortisol test in specific situations (Fig. 1, 1QEEE).”
§ The Diagnosis of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline > METHOD OF DEVELOPMENT OF EVIDENCE-BASED RECOMMENDATIONS
“strong recommendations use the phrase "we recommend" and the number 1, and weak recommendations use the phrase "we suggest" and the number 2.”
Citations
Cites
Grading quality of evidence and strength of recommendations
(2004) · BMJ · doi:10.1136/bmj.328.7454.1490 · Cited by 8,477 · cited 1×
“with expertise in development and implementation of evidencebased guidelines (1).”
BackgroundCushing, H. (1964) · Journal of Neurosurgery · doi:10.3171/jns.1964.21.4.0318 · Cited by 851 · cited 1×
“6 yr, and in 1952 a 5-yr survival of just 50%, with most deaths caused by vascular (myocardial infarction, cerebrovascular accident) or infectious complications (11, 12).”
BackgroundThe Diagnosis and Differential Diagnosis of Cushing’s Syndrome and Pseudo-Cushing’s States
Newell-Price, J., Trainer, P., Besser, M., & Grossman, A. (1998) · Endocrine Reviews · doi:10.1210/edrv.19.5.0346 · Cited by 833
Self-citationGold, P. W., Loriaux, D. L., Roy, A., Kling, M. A., Calabrese, J. R., Kellner, C. H., Nieman, L. K., Post, R. M., Pickar, D., Gallucci, W., et al. (1986) · New England Journal of Medicine · doi:10.1056/nejm198605223142101 · Cited by 766
Self-citationThe natural history of cushing's syndrome
Plotz, C. M., Knowlton, A. I., & Ragan, C. (1952) · The American Journal of Medicine · doi:10.1016/0002-9343(52)90027-2 · Cited by 763 · cited 1×
“6 yr, and in 1952 a 5-yr survival of just 50%, with most deaths caused by vascular (myocardial infarction, cerebrovascular accident) or infectious complications (11, 12).”
BackgroundTESTS OF PITUITARY-ADRENAL SUPPRESSIBILITY IN THE DIAGNOSIS OF CUSHING'S SYNDROME*
LIDDLE, G. W. (1960) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-20-12-1539 · Cited by 735
Taking Glucocorticoids by Prescription Is Associated with Subsequent Cardiovascular Disease
Wei, L., MacDonald, T. M., & Walker, B. R. (2004) · Annals of Internal Medicine · doi:10.7326/0003-4819-141-10-200411160-00007 · Cited by 730 · cited 1×
“These data are consistent with the increased cardiovascular mortality and morbidity reported in patients with iatrogenic Cushing’s syndrome secondary to the chronic use of synthetic corticosteroids (15).”
ResultMeasurements of Serum Free Cortisol in Critically Ill Patients
Hamrahian, A. H., Oseni, T. S., & Arafah, B. M. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa020266 · Cited by 726 · cited 1×
“are associated with decreased serum cortisol values (39, 46).”
BackgroundMorbidity and mortality in Cushing's disease: an epidemiological approach.
Etxabe, J., & Vazquez, J. A. (1994) · Clinical Endocrinology · doi:10.1111/j.1365-2265.1994.tb02486.x · Cited by 622 · cited 2×
“0-fold, compared with the general population (4, 5).”
BackgroundIncidence and Late Prognosis of Cushing’s Syndrome: A Population-Based Study1
Lindholm, J., Juul, S., Jørgensen, J. O. L., Astrup, J., Bjerre, P., Feldt-Rasmussen, U., Hagen, C., Jørgensen, J., Kosteljanetz, M., Kristensen, L. Ø., et al. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.1.7093 · Cited by 619 · cited 6×
“Because some patients with Cushing’s disease demonstrate suppressibility to dexamethasone, use of this diagnostic criterion J Clin Endocrinol Metab, May 2008, 93(5):1526–1540 jcem.”
BackgroundInfluential
Cited by
Items 2,601–2,700 of 2,716
Pazmiño, C., Baudrand, R., Uslar, T., Guarda, F. J., Xavier, A., Manjarres, L., Vassiliu, M., Besa, C., & Andía, M. E. (2026) · Research Square · doi:10.21203/rs.3.rs-8398852/v1
CXCR4 serves as a new pathological biomarker for cortisol-producing adenomasPreprint
Yang, X., Yang, Y. A., Li, J., et al. (2026) · Research Square · doi:10.21203/rs.3.rs-8269823/v1
Bilateral Central Serous Chorioretinopathy in a Patient With XYY Syndrome
Adibnia, Y., Meshkin, R. S., Pandiri, S., Chaaya, C., Vavvas, D. G., & Patel, N. A. (2026) · Ophthalmic surgery, lasers & imaging retina · doi:10.3928/23258160-20251112-02
AKKUŞ, G. Y., Karagün, B., Cetinalp, N. E., et al. (2020) · DergiPark (Istanbul University)
Animal models of CS: What do they teach us?
Kirschner, L. S. (2026) · Elsevier eBooks · doi:10.1016/b978-0-323-96100-4.00019-3
Factitious Cushing syndrome and factitious Cushing syndrome-by-proxy: Cases, diagnosis, and outcomes
Keil, M. F. (2026) · Elsevier eBooks · doi:10.1016/b978-0-323-96100-4.00013-2
Adrenal tumors causing Cushing syndrome: Genetics, molecular advances, diagnosis, and treatment
Vaduva, P., Violon, F., & Bertherat, J. Y. (2026) · Elsevier eBooks · doi:10.1016/b978-0-323-96100-4.00017-x
Bompoula, M. S., & Kalantaridou, S. (2026) · Elsevier eBooks · doi:10.1016/b978-0-323-96100-4.00006-5
Cushing syndrome in pediatrics: From molecular pathogenesis to therapeutic management
Nicolaides, N. C., & Stratakis, C. A. (2026) · Elsevier eBooks · doi:10.1016/b978-0-323-96100-4.00021-1
Ectopic ACTH- or CRH-producing tumors and Cushing’s syndrome
Kefeli, M., & Mete, Ö. (2026) · Elsevier eBooks · doi:10.1016/b978-0-323-96100-4.00002-8
All about dexamethasone testing in Cushing's syndrome
Violetis, O., Alexandraki, K., & Grossman, A. B. (2026) · Elsevier eBooks · doi:10.1016/b978-0-323-96100-4.00015-6
Nonneoplastic hypercortisolism (pseudo-CS): Causes and long-term issues
Ferrière, A., & Tabarin, A. (2026) · Elsevier eBooks · doi:10.1016/b978-0-323-96100-4.00020-x · Cited by 1
Surgical management of CD: Techniques, complications, and recovery
Laws, M. T., Rampalli, I., & Chittiboina, P. (2026) · Elsevier eBooks · doi:10.1016/b978-0-323-96100-4.00003-x
Haberbosch, L., Faßnacht, M., Reincke, M., Kabilka, A., Effenberger, T., Hupp, T., Tuckermann, J. P., Petersenn, S., & Kreitschmann‐Andermahr, I. (2026) · Das Gesundheitswesen · doi:10.1055/a-2776-2466
Anzà, S., Rosa, B. A., Herzberg, M. P., Lee, G., Herzog, E. D., Zhao, P., England, S. K., Ndao, I. M., Martin, J., Smyser, C. D., et al. (2026) · medRxiv · doi:10.64898/2026.02.23.26346831
Hepatic embolization for Cushing syndrome from metastatic tumors: a single-center case series
Zhang, S., Mosquera, J. E., Musonza, C., Pillai, A., Abramowitz, J. D., Mirfakhraee, S., Polanco, P. M., Mutar, S. S. A., Arafat, W., & Hamidi, O. (2026) · Journal of the Endocrine Society · doi:10.1210/jendso/bvag046
“However, in patients with metastatic disease, such as ACC or ectopic ACTH-producing tumors, surgical options are often limited due to extensive tumor burden at diagnosis or poor functional status [12].”
Srinivasan, H., Shridevi, K., Mohanty, S., et al. (2026) · Obesity Medicine · doi:10.1016/j.obmed.2026.100688
New tools for the diagnosis of hypercortisolism
Zhao, Q., Sima, O.-C., Estapé, M., Casals, G., & Hanzu, F. A. (2026) · Vitamins and hormones · doi:10.1016/bs.vh.2026.02.007
Management of Cushing’s Disease in Pregnancy: A Case Report
Mukherjee, G., Manmathan, S., Zachariah, S., Arokisamy, J., & Kar, S. K. (2026) · Cureus · doi:10.7759/cureus.105582
“In the present case, the patient had a pre-established diagnosis of Cushing’s syndrome secondary to a pituitary microadenoma, and was awaiting gadolinium-enhanced MRI for further evaluation [8].”
Cushing-Syndrom (Hyperkortisolismus) im Kindesalter
Kamrath, C., & Wudy, S. A. (2025) · Elsevier eBooks · doi:10.1016/b978-3-437-21447-9.50064-7
NK/T cell lymphoma-induced ectopic ACTH syndrome: a case report
Xu, S., Lü, D., Zhao, X., et al. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1745880
Cardiometabolic Burden in Bilateral Macronodular Adrenal Disease With Primary Aldosteronism
Panarelli, A., Araujo-Castro, M., Mermejo, L. M., Turcu, A. F., Kim, J. H., Park, S. S., Bioletto, F., Parasiliti‐Caprino, M., Sone, M., Markou, Α., et al. (2026) · Hypertension · doi:10.1161/hypertensionaha.125.25507
Mangone, A., Sala, E., Carosi, G., Sindaco, G. D., Mungari, R., Cremaschi, A., Petria, I., Noschese, G., Lotito, V., Mantovani, G., et al. (2026) · Pituitary · doi:10.1007/s11102-026-01668-8
“In such cases, management strategies include repeating surgery, radiotherapy and medical therapies [ 1, 2 ].”
Génomique intégrée des tumeurs bénignes corticosurrénaliennes
Faillot, S. (2017) · theses.fr (ABES) · doi:10.70675/36869127z1fb2z41bbzb082z1048e489a8e6
Elenius, H., Findling, J. W., Tabarin, A., & Nieman, L. K. (2026) · Journal of the Endocrine Society · doi:10.1210/jendso/bvag061
Self-citationAbsent nocturnal cortisol decline in Pheochromocytoma: A retrospective study
Sun, Y., Kometani, M., Aiga, K., Mai, X., Konishi, S., Kadono, M., Gondoh, Y., & Yoneda, T. (2026) · Steroids · doi:10.1016/j.steroids.2026.109779
Implication du récepteur des glucocorticoïdes en physiopathologie humaine
Vitellius, G. (2019) · theses.fr (ABES) · doi:10.70675/84630f11zbc82z43a6z8604z69024f4ae7dd
Bonnet-Serrano, F. (2021) · theses.fr (ABES) · doi:10.70675/022bf2ffz5b62z4303z9460z55629099aab6
Morelli, V., Strata, M., Palmieri, S., Aresta, C., Favero, V., Frigerio, S., Pugliese, F., Musolino, A., Dall'Antonia, A., Corbetta, S., et al. (2026) · Journal of Endocrinological Investigation · doi:10.1007/s40618-026-02872-w · Cited by 3
“…or symptoms specific of hypercortisolism; 4) possible meta - static diseases or radiologic appearance not consistent with an adrenocortical adenoma; 5) biochemical evidence of pheochromocytoma and primary aldosteronism; 6) ACTH-dependent hypercortisolism [16]; 7) incomplete diagnostic work-up.”
Chasseloup, F. (2022) · theses.fr (ABES) · doi:10.70675/ddec5b6dzf376z4aadz9970zf0bf052c6f02
Ectopic ACTH-dependent Cushing syndrome due to mature ovarian teratoma
Eisa, N. (2026) · BMJ Case Reports · doi:10.1136/bcr-2025-271716
Jangamani, R., Subramanian, V. B., Khan, M. F., Siddini, V., Ballal, S. H., & Hegde, A. G. (2026) · Annals of Medical Science and Research · doi:10.4103/amsr.amsr_71_25
Hypercortisolism: A Prevalent and Complicating Factor in Primary Aldosteronism
Pasricha, S. V., Seav, S. M., Hung, M. L., & Bhalla, V. (2026) · Hypertension · doi:10.1161/hypertensionaha.126.26810
Nasi‐Kordhishti, I., Hladík, M., Behling, F., Schittenhelm, J., & Honegger, J. B. (2026) · Pituitary · doi:10.1007/s11102-026-01675-9
“Cushing’s disease (CD) is caused by an adrenocorticotropic hormone (ACTH)-secreting pituitary tumor, which leads to hypercortisolism and considerable morbidity [1– 3 ].”
Biases of large language models in diagnosing Cushing’s syndrome
Savvidis, C., Liakopoulos, C., & Ilias, Ι. (2026) · World Journal of Methodology · doi:10.5662/wjm.v16.i2.115059
Ectopic Cushing’s syndrome: Clinical presentation and diagnosis
Morelli, V., & Musolino, A. (2026) · Vitamins and hormones · doi:10.1016/bs.vh.2026.02.003
Biochemical diagnosis of hypercortisolism: When and how?
Asla, Q., Urgell, E., Terzan, S., Marín, R., Vives, A. S., Webb, S. M., & Aulinas, A. (2026) · Vitamins and hormones · doi:10.1016/bs.vh.2026.03.001
Sun, G. (2026) · Springer eBooks · doi:10.1007/978-3-031-90919-1_33-1
Endocrine Disorders and Tumors
Santore, M. T., Clifton, M. S., & Alemayehu, H. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-12431-0.00072-3
Siddiq, F., Brooks, H., Demirtas, E., Bhatti, I. A., Kasab, S. A., de Havenon, A., Novakovic, R., Mansour, O. Y., Kenmuir, C. L., Hassan, A. E., et al. (2026) · Stroke Vascular and Interventional Neurology · doi:10.1161/svin.125.002309 · Cited by 3
A Challenging Diagnosis of Cushing’s Syndrome in Primary Care: A Case Report
Ferreira, M. F., Valente, F., Correia, R., & Apolinário, P. (2026) · Cureus · doi:10.7759/cureus.108265
van Houten, P., van de Ven, A. C., van Herwaarden, A. E., Netea, M. G., Jaeger, M., & Netea-Maier, R. T. (2026) · Journal of Clinical & Translational Endocrinology · doi:10.1016/j.jcte.2026.100443
Combination of magnetic bead extraction and LC–MS/MS detection for the detection of saliva cortisol
Zhu, L., Chen, T., Ni, J., Lu, J., Lu, W., Han, W., Dou, Q., & Zhou, J. (2026) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-026-06527-w
“Compared with blood sampling, saliva collection is noninvasive and better suited to repeated sampling, making it particularly advantageous for dynamic monitoring of cortisol fluctuations [1].”
ACTH independent Cushing’s syndrome: Diagnosis and etiology
Ortiz-Flores, A. E. (2026) · Vitamins and hormones · doi:10.1016/bs.vh.2026.02.001
Presentation and clinical patterns of bilateral adrenal lesions: a retrospective cohort study
Lu, H., Aggarwal, E., Hodhod, A., Achenbach, S. J., Atkinson, E. J., Yu, K., Powell, C. M., & Bancos, I. (2026) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgag199
Martínez, W. A. R., Builes-Montaño, C. E., Román-González, A., Barrera, C. A. B., Castaño, M. J. R., & Gutiérrez-Restrepo, J. (2026) · Vitamins and hormones · doi:10.1016/bs.vh.2026.03.002
Cyclical ectopic Cushing’s syndrome due to a mediastinal neuroendocrine tumor: a case-based review
Peixe, C., Lopes, M. V., Severino, M. D. G., et al. (2026) · Irish Journal of Medical Science (1971 -) · doi:10.1007/s11845-026-04432-w
Störungen des Cortisol-Haushaltes
Osswald-Kopp, A. (2026) · CME · doi:10.1007/s11298-026-4573-8
Cut-off values of urinary free cortisol and cortisone for diagnosing neoplastic hypercortisolism
Koops, K., Hillebrand, J. J., Heijboer, A. C., & Bisschop, P. H. L. T. (2026) · Clinica Chimica Acta · doi:10.1016/j.cca.2026.121107
Pennington, S., Prasad, A. B., & Murphy, S. (2026) · BMJ Case Reports · doi:10.1136/bcr-2026-272173
Cyclic Cushing syndrome as a clinical enigma and diagnostic dilemma in advanced endocrinology
Ilkiv, Y., Potapova, K., Yerokhovych, V., & Kobyliak, N. M. (2026) · Journal of Endocrinological Investigation · doi:10.1007/s40618-026-02910-7
“The Endocrine Society recommends LNSC and UFC over DST for suspected CCS [39].”
Adrenocorticotropin-secreting pituitary macroadenomas: expanding the clinical spectrum
Iyer, C., Havenga, N., Roytowski, D., Davis, R., Zaharie, D., & Conradie-Smit, M. (2026) · JCEM Case Reports · doi:10.1210/jcemcr/luag127
“Biochemical assessment included UFC, midnight serum cortisol, ACTH levels, DST, and assessment of pituitary function [10].”
InfluentialApproach to the patient: investigation of postmenopausal androgen excess
Madden-Doyle, L., Bowers, K., Sherlock, M., & O’Reilly, M. (2026) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgag221 · Cited by 1
Modest sensitivity of 24 h urine free cortisol LC-MS/MS to detect Cushing's disease
Lithgow, K. C., Mann, J. A., Starreveld, Y. P., Orton, D. J., Venos, E., Leung, A. A. C., & Kline, G. A. (2026) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2026.111147
Gupta, G. H., & Kumar, S. (2026) · ACS Applied Nano Materials · doi:10.1021/acsanm.6c01838
Turkkan, C. Y., Canat, M. M., Gol, H. E., & Altuntas, Y. (2026) · International Journal of Endocrinology · doi:10.1155/ije/2517065
Steinkogler, A., Zopp, S., Albani, A., Theodoropoulou, M., Stüfchen, I., Schweizer, J. R. D. O. L., Völter, F., Ritzel, K., Moser, K., Schilbach, K., et al. (2026) · Pituitary · doi:10.1007/s11102-026-01686-6
“Diagnosis and subtyping in both cohorts followed standardised clinical and biochemical protocols published previously [17, 18] according to current guidelines [19, 20].”
Laboratory Evaluation of the Hypothalamic-Pituitary-Adrenal Axis
Greere, D., & Păun, D. L. (2026) · IntechOpen eBooks · doi:10.5772/intechopen.1016109
Ectopic ACTH-producing pheochromocytoma in a patient with an APC gene mutation: A case report
Gil-Santos, S., Calheiros, R., Salazar, D., Oliveira, J., Fernandes, M., Cunha, A. L., Santos, C., Conde, S., Verdelho, A. J., & Santos, A. P. (2026) · Endocrinología Diabetes y Nutrición (English ed ) · doi:10.1016/j.endien.2026.501741
Zhao, L., Liu, J., Li, N., Wei, Y., Wang, P., Li, J., & Zhang, S. (2026) · BMC Endocrine Disorders · doi:10.1186/s12902-026-02333-8
“This assay directly quantifies bioactive free cortisol, independent of variations in cortisol-binding globulin levels [25, 26], making it a first-line screening tool for CS.”
Olesrud, I., Andersen, M. K., Larsson, C., Heck, A., Dahlberg, D., & Wiedmann, M. K. H. (2026) · Brain and Spine · doi:10.1016/j.bas.2026.106144 · Cited by 1
“In Cushing's disease, remission was defined as a nadir plasma cortisol value 138 nmol/L measured within the first 7 postoperative days (Nieman et al., 2008).”
Koops, K., Heijboer, A. C., Bisschop, P. H. L. T., & Hillebrand, J. J. (2026) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgag249
Bass, I. R., Nosova, E. V., & Dunaif, A. E. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-45863-7.00085-8
Shrestha, K. L., Lee, E., Ramakrishnan, N., Lee, J., Choi, Y., Lee, S. J., Yu, Y., Kim, J. K., Yang, S.-H., Kim, J., et al. (2026) · ACS Sensors · doi:10.1021/acssensors.6c01339
Vivekanand, B., Sethi, K., Sharma, E., Soumya, S., & Andrade, C. (2026) · Asian Journal of Psychiatry · doi:10.1016/j.ajp.2026.105077
Research Progress in Diagnostic Methods of Cushing’s Syndrome
郭, 林. (2026) · Advances in Clinical Medicine · doi:10.12677/acm.2026.1662449
Rare causes of exogenous Cushing’s Syndrome: a challenge for endocrinologists
Picciola, V. M., Medici, M., Ambrosio, M. R., & Zatelli, M. C. (2026) · Journal of Endocrinological Investigation · doi:10.1007/s40618-026-02970-9
Sham, T.-T., Zhou, Y., Smith, B. L., Blair, J., & Maher, S. (2026) · Analytica Chimica Acta · doi:10.1016/j.aca.2026.345923
Diagnostic work-up in paediatric adrenocortical tumours: an international consensus
Antonini, S. R. R., Wiegering, V., Halah, M. P., Pinto, L. E. C., Atapattu, N., Md, P., Elias Jr., J., Eker, N., Faßnacht, M., Fragoso, M. C. B. V., et al. (2026) · European Journal of Endocrinology · doi:10.1093/ejendo/lvag086
Kurudagi, N., Sajjan, B., Morabad, S. S., Goornavar, S. M., & Hegde, P. R. (2026) · Cureus · doi:10.7759/cureus.112250
“Metabolic disturbance accompanied the cutaneous picture: hypertension was documented in two patients and symptomatic hyperglycaemia in one, consistent with the established effects of cortisol on vascular tone, insulin sensitivity, and glucose metabolism [2].”
InfluentialLow work ability and high disability burden in Cushing’s syndrome: a multicenter cohort study
Steinkogler, A., Zopp, S., Moser, K., Schweizer, J. R. D. O. L., Stüfchen, I., Völter, F., Ritzel, K., Rubinstein, G., Braun, L. T., Theodoropoulou, M., et al. (2026) · Journal of Endocrinological Investigation · doi:10.1007/s40618-026-02966-5
Referral to Definitive Surgical Treatment in Cushing's Syndrome – An Odyssey That Requires Attention
Coulden, A., Arshad, A., Diddhenipothage, S. A. D. M., Aylwin, S. J. B., Mamoojee, Y. H., Flanagan, D., Pal, A., Gittoes, N. J. L., & Gleeson, H. K. (2026) · Clinical Endocrinology · doi:10.1111/cen.70175
Rubinstein, G., Fedtke, V., Then, C., Nowak, E., Vogel, F., Braun, L., Zopp, S., Zimmermann, P., Peters, A., Heier, M., et al. (2026) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2026.113436
Annexin A1 as a diagnostic biomarker for cyclic Cushing disease
Rao, Z., Wu, L., Jiang, L., Su, T., Cao, Y., Lin, S., 何虾娣, Ye, Y., Ning, G., Wang, W., et al. (2026) · iScience · doi:10.1016/j.isci.2026.116907
If it is in the adrenal gland, it is not essential (hypertension)
Kramm, C., & Lockette, W. E. (2026) · Current Problems in Surgery · doi:10.1016/j.cpsurg.2026.102133
Adrenocorticotropic hormone-independent Cushing syndrome
Ramamurthy, P., Pooja, U. K., Santhosh, T., & Ganavi, Y. P. (2026) · The National Medical Journal of India · doi:10.25259/nmji_879_2024
Eisa, N., Khoury, M., & Barood, O. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.71161
A challenging diagnosis of pediatric (cyclic) Cushing disease: the decisive role of hair cortisol
Berkenbosch, L., & Straetemans, S. (2026) · JCEM Case Reports · doi:10.1210/jcemcr/luag195
“Subsequent diagnostic tests for CS, as recom - mended by the Endocrine Society Clinical Practice Guideline, yielded conflicting results [10].”
Waki, R., Ishida, A., Matsuoka, G., Takano, K., Fukuhara, N., Takeshita, A., Oki, Y., & Yamada, S. (2026) · Pituitary · doi:10.1007/s11102-026-01741-2
Detomas, M., Prada, J. P., Altieri, B., Stüfchen, I., Nasi‐Kordhishti, I., Wolfsberger, S., Losa, M., Quinkler, M. O., Kimpel, O., Vila, G., et al. (2026) · European Journal of Endocrinology · doi:10.1093/ejendo/lvag141
Marchand, M. (2025) · Elsevier eBooks · doi:10.1016/b978-2-294-78647-1.00015-x
Şensoy, E., Gediz, B. Ş., Fırat, S. N., & Kaya, P. Ç. (2026) · Journal of Current Ophthalmology · doi:10.4103/joco.joco_271_25 · Cited by 1
“7,8 Several reports have revealed an increase in CT in relation to high serum cortisol levels in patients with CS. 13,14 Since SCS causes changes in systemic vascular structures, it may be reasonable to investigate whether choroidal parameters would be useful in the prediction or management of…”
Herbstein, F., Rosmino, J., Budnik, N., et al. (2026) · Journal of Endocrinological Investigation · doi:10.1007/s40618-026-03012-0
Pooja, R., Jha, V., Kundu, K., Kaur, J., Sharma, B., Chhabra, R., Singh, A., Dhandapani, S., Sahoo, S. K., Bhadada, S. K., et al. (2026) · Clinical Endocrinology · doi:10.1111/cen.70200
Krylov, V. V., Usachev, D. Y., Grigoriev, A. Y., Cherebillo, V. Y., Kalinin, P. L., Kutin, M. A., Pashaev, B., Rudenko, P. G., Gormolysova, E., Dedov, I. I., et al. (2026) · Endocrine Surgery · doi:10.14341/serg13053 · Cited by 1
Night eating in Cushing’s disease: Disentangling psychological, sleep, and endocrine contributions
Sağlam, N. G. U., Tunc, A., Altunel, M. R., Soltanova, L., Kırpınar, M. M., Şahin, S., Özkaya, H. M., Turan, Ş., & Kadıoğlu, P. (2026) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2026.107997
Adrenocortical Carcinoma with Suspected Dual Cortisol and Aldosterone Secretion: A Case Report
Jaime, C. F., & Gan, F. R. (2026) · Journal of the ASEAN Federation of Endocrine Societies · doi:10.15605/jafes.041.02.5875
“3 The diagnosis of ACCs involves biochemical testing, followed by surgical resection and histopathologic confirmation.”
Özcan, Ö., Koops, K., Hillebrand, J. J., et al. (2026) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2026-0410
“Measurement of 24-h urine free cortisol (UFC) is widely recommended as one of the fi rst-line screening tests, as it re fl ects total cortisol production over 24 h and provides a direct assessment of circulating active cortisol independent of corticosteroid-binding globulin levels [4 – 6].”
InfluentialHypercortisolism: An Under‐Recognised Pathway Linked to Multi‐System Complications
Sacoto, H. D., & Fonseca, V. A. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.71149
Takemoto, M., Obata, Y., Mitsui, Y., & Shimomura, I. (2026) · JCEM Case Reports · doi:10.1210/jcemcr/luag237
“Because the circadian rhythm of cortisol secretion is preserved during pregnancy, midnight cortisol measurement is considered useful for diagnosing CS [3, 23].”
Ikeda, K., Nakamura, S., Sekine, N., Kadowaki, S., Sugimoto, D., & Satoh, H. (2026) · JCEM Case Reports · doi:10.1210/jcemcr/luag229 · Cited by 2
“False-positive results may occur because of inadequate dexamethasone exposure, medication effects on dexamethasone metabolism, altered cortisol-binding globulin, or other confounders [7].”
Mild Autonomous ACTH Secretion: A Narrative Review of 52 Cases from the Literature
Nicoli, F., Eller-Vainicher, C., Cozzi, R. C., Chiodini, I., & Favero, V. (2026) · Endocrine Practice · doi:10.1016/j.eprac.2026.08.016
Adrenal incidentalomas: 1 mg dexamethasone test result in the context of cardiometabolic risk
Kokoszka, J., Opalińska, M., Fiema, M., Sitarz, K., Matrejek, A., Banaś, A., Pabian, G., Musiał, K., Gilis‐Januszewska, A., Sztefko, K., et al. (2026) · Journal of Endocrinological Investigation · doi:10.1007/s40618-026-03035-7
Cakir, M. C., Aydemir, M., Oral, O., et al. (2026) · British Journal of Hospital Medicine · doi:10.31083/bjhm57289
Liu, Y., Yi, L., & Tan, H. (2026) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgag361
Pekmezci, A., Arıkan, M. A., Kuzu, İ., Yilmaz, M. K., Arikan, C. C., Burhan, Ş., Uzman, R. D. T., Acarer, D., Yardımcı, A. H., Niyazoğlu, M., et al. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1959212
“Cushing ’ s disease was de fi ned as endogenous hypercortisolism secondary to an adrenocorticotropic hormone (ACTH) – secreting pituitary adenoma, con fi rmed by standard biochemical testing and pituitary imaging (22).”
Endocrine Evaluation of Hyperandrogenism in Women
Grennan, K., & Chang, A. Y. (2026) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2026.07.005
Castro, M. A., Bancos, I., Detomas, M., Reincke, M., Kaštelan, D., Naglic, M., Nekić, A. B., Biagetti, B., Casteràs, A., Cardona-Arias, A., et al. (2026) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgag373
High-salt diet modulates endocrine regulation between cortisol and FGF23
Moor, M. B., Sagmeister, M. S., Crastin, A., Kopper, K., Péchère-Bertschi, A., Hardy, R. S., Féraille, E., Fuster, D. G., Loffing, J., & Pathare, G. (2026) · Pflügers Archiv - European Journal of Physiology · doi:10.1007/s00424-026-03211-x
“Furthermore, both cortisol and FGF23 are used in many diagnostic tests [30, 36].”
Metadata
- Authors
- Nieman, L. K., Biller, B. M. K., Findling, J. W., Newell-Price, J., Savage, M. O., Stewart, P. M., & Montori, V. M.
- Affiliations
- National Institutes of Health (US)
- Massachusetts General Hospital (US)
- Medical College of Wisconsin (US)
- University of Sheffield (GB)
- Queen Mary University of London (GB)
- University of Birmingham (GB)
- Mayo Clinic (V.M.M.), Rochester, Minnesota 55905
- ORCID
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2008-05-01
- Volume
- 93
- Issue
- 5
- Pages
- 1526-1540
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- PMC
- PMC2386281
- OpenAlex
- W1990995386
- Cited by
- 2,718
- References
- 140
- Citations by year
- 2026: 159 · 2025: 173 · 2024: 173 · 2023: 148 · 2022: 212 · 2021: 199 · 2020: 195 · 2019: 165 · 2018: 150 · 2017: 148 · 2016: 158 · 2015: 156 · 2014: 134 · 2013: 139 · 2012: 114
- FWCI
- 70.23
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- University of Birmingham Research Portal (University of Birmingham) (submittedVersion)
- Funders
- European Society of Endocrinology
- National Institutes of Health
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (Z01HD008833)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pituitary Gland Disorders and Treatments
- Health Sciences › Medicine › Surgery › Adrenal and Paraganglionic Tumors
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
- Keywords
- Cushing's syndrome, diagnosis, hypercortisolism, adrenal incidentaloma, dexamethasone suppression test, late-night salivary cortisol, urine cortisol
- MeSH terms
- Cushing Syndrome, Dexamethasone, Humans, Hydrocortisone, Saliva, Evidence-Based Medicine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-09-28, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-09-28 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.